AstraZeneca’s Phase 3 Farxiga data impresses in type 2 diabetes
AstraZeneca has presented new Phase 3 data at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco on its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), demonstrating that the drug successfully reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D).
Derived from 17,160 T2D patients with predominantly reserved renal function irrespective of underlying atherosclerotic CV disease (ASCVD), the data revealed that Farxiga reduced the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease and renal death by 47% compared to placebo.
Additionally, the drug also reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular (CV) death by 24% compared to placebo, and demonstrated a lower incidence of ESRD compared to placebo.
“Heart failure and renal diseases are two of the most common and early complications experienced by people living with type-2 diabetes, and are too often overlooked,” commented AZ’s Elisabeth Björk, Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D. “They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga.”
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …